CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Luca Issi raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $50.00 (from $42.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
